EUVIMEDEUVIMED entdecken
EditorialKommentar

New Antibiotics for Resistant Infections: What Happens After Approval?

Jessica Howard-Anderson, Helen W Boucher

Annals of Internal Medicine · 2024

DOI: 10.7326/m24-0192 ↗

Kurz gefasst

Editorial in der Zeitschrift Annals of Internal Medicine, 2024. Verfasst von Jessica Howard-Anderson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Drug Approval, United States Food and Drug Administration. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsDrug ApprovalUnited States Food and Drug AdministrationHumansUnited StatesDrug Resistance, Bacterial

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
  • Tufts University School of Medicine and Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts.

Zitieren

APA

Howard-Anderson, J., & Boucher, H. W. (2024). New Antibiotics for Resistant Infections: What Happens After Approval?. Annals of Internal Medicine. https://doi.org/10.7326/m24-0192

Vancouver

Howard-Anderson J, Boucher HW. New Antibiotics for Resistant Infections: What Happens After Approval?. Annals of Internal Medicine. 2024. doi:10.7326/m24-0192

BibTeX
@article{HowardAnderson2024,
  author = {Howard-Anderson, Jessica and Boucher, Helen W},
  title = {New Antibiotics for Resistant Infections: What Happens After Approval?},
  journal = {Annals of Internal Medicine},
  year = {2024},
  doi = {10.7326/m24-0192}
}
Kostenlos starten →